Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphological and molecular comparison of HIV-associated and sporadic inclusion body myositis.

Journal of neurology·2023
Same author

[Neurological complications of hepatitis C infections].

Der Nervenarzt·2020
Same author

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2019
Same author

Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience.

Journal of neurovirology·2019
Same author

HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.

Journal of neurology·2017
Same author

[Update HIV and neurology].

Deutsche medizinische Wochenschrift (1946)·2015

Related Experiment Video

Updated: Jan 10, 2026

TACI: An ImageJ Plugin for 3D Calcium Imaging Analysis
09:39

TACI: An ImageJ Plugin for 3D Calcium Imaging Analysis

Published on: December 16, 2022

5.0K

TMC-125 Tibotec.

Bernhard A Haslinger1, Gabriele Arendt

  • 1University Düsseldorf, Department of Neurology, Postfach 10 10 07, D-40001 Düsseldorf, Germany.

Current Opinion in Investigational Drugs (London, England : 2000)
|March 27, 2004
PubMed
Summary
This summary is machine-generated.

Tibotec is developing TMC-125, a non-nucleoside reverse transcriptase inhibitor, for HIV treatment. Phase II trials are underway in treatment-naive and experienced individuals, with a Phase IIb study ongoing.

More Related Videos

Conventional and Threshold-Tracking Transcranial Magnetic Stimulation Tests for Single-handed Operation
08:24

Conventional and Threshold-Tracking Transcranial Magnetic Stimulation Tests for Single-handed Operation

Published on: August 16, 2021

6.5K
Thermal Scanning Conductometry TSC as a General Method for Studying and Controlling the Phase Behavior of Conductive Physical Gels
10:01

Thermal Scanning Conductometry TSC as a General Method for Studying and Controlling the Phase Behavior of Conductive Physical Gels

Published on: January 23, 2018

8.0K

Related Experiment Videos

Last Updated: Jan 10, 2026

TACI: An ImageJ Plugin for 3D Calcium Imaging Analysis
09:39

TACI: An ImageJ Plugin for 3D Calcium Imaging Analysis

Published on: December 16, 2022

5.0K
Conventional and Threshold-Tracking Transcranial Magnetic Stimulation Tests for Single-handed Operation
08:24

Conventional and Threshold-Tracking Transcranial Magnetic Stimulation Tests for Single-handed Operation

Published on: August 16, 2021

6.5K
Thermal Scanning Conductometry TSC as a General Method for Studying and Controlling the Phase Behavior of Conductive Physical Gels
10:01

Thermal Scanning Conductometry TSC as a General Method for Studying and Controlling the Phase Behavior of Conductive Physical Gels

Published on: January 23, 2018

8.0K

Area of Science:

  • Virology
  • Pharmacology
  • Clinical Trials

Background:

  • Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge.
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a key class of antiretroviral drugs.
  • TMC-125 is an investigational NNRTI developed by Tibotec.

Purpose of the Study:

  • To evaluate the safety and efficacy of TMC-125 for HIV treatment.
  • To determine optimal dosing for TMC-125 in a Phase IIb study.

Main Methods:

  • Phase IIa clinical trials were completed in treatment-naive and treatment-experienced HIV-1-infected individuals.
  • A long-term, Phase IIb, dose-finding study was initiated in treatment-experienced patients.
  • Patient enrollment occurred across European countries and Canada.

Main Results:

  • Phase IIa trials in both patient groups were completed by February 2002.
  • The Phase IIb study commenced enrollment in 2002 (Europe) and 2003 (Canada).

Conclusions:

  • TMC-125 is progressing through clinical development for HIV therapy.
  • Ongoing studies aim to establish TMC-125's role in managing HIV infection.